Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Tarsus Pharmaceuticals, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 116
- +11 vs. Q3 2023
- Shares held
- 32.2M
- +2.39M (+8.0%) vs. Q3 2023
- Total value
- $652.0M
- +$122.5M (+23.1%) vs. Q3 2023
- New holders
- 28
- 48 more added
- Sold out
- 17
- 22 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TARS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 256 | $2.98B |
| Q1 2026 | 253 | $3.17B |
| Q4 2025 | 246 | $3.61B |
| Q3 2025 | 220 | $2.67B |
| Q2 2025 | 205 | $1.87B |
| Q1 2025 | 195 | $2.26B |
| Q4 2024 | 195 | $2.23B |
| Q3 2024 | 162 | $1.43B |
| Q2 2024 | 148 | $1.09B |
| Q1 2024 | 157 | $1.43B |
| Q4 2023 | 116 | $652.0M |
| Q3 2023 | 105 | $529.4M |
| Q2 2023 | 92 | $387.3M |
| Q1 2023 | 74 | $252.1M |
| Q4 2022 | 69 | $301.0M |
| Q3 2022 | 75 | $350.8M |
| Q2 2022 | 73 | $291.7M |
| Q1 2022 | 51 | $222.2M |
| Q4 2021 | 43 | $294.2M |
| Q3 2021 | 44 | $277.4M |
| Q2 2021 | 44 | $378.5M |
| Q1 2021 | 41 | $410.4M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Tarsus Pharmaceuticals, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 518,519 | $10.5M | 2.87% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 609,736 | $12.3M | 0.00% | +83,476+15.9% | Added |
| State Street Corp | 674,831 | $13.7M | 0.00% | +129,899+23.8% | Added |
| Polygon Management Ltd. | 800,000 | $16.2M | 4.11% | +185,000+30.1% | Added |
| Paradigm Biocapital Advisors LP | 1,025,000 | $20.8M | 0.97% | +1,025,000 | New |
| TCG Crossover Management, LLC | 1,142,857 | $23.1M | 2.57% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 1,296,416 | $26.3M | 0.59% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,595,501 | $32.3M | 0.00% | +43,699+2.8% | Added |
| Vivo Capital, LLC | 1,784,006 | $36.1M | 2.96% | −478,194−21.1% | Reduced |
| Frazier Life Sciences Management, L.P. | 1,787,527 | $36.2M | 1.94% | 00.0% | Unchanged |
| Cowen and Company, LLC | 1,911,399 | $38.7M | 2.54% | +114,626+6.4% | Added |
| Morgan Stanley | 1,957,688 | $39.6M | 0.00% | +1,883,869+2,552.0% | Added |
| Tang Capital Management LLC | 2,204,797 | $44.6M | 4.13% | +64,211+3.0% | Added |
| Cormorant Asset Management, LP | 2,221,422 | $45.0M | 2.15% | −400,000−15.3% | Reduced |
| BlackRock Inc. | 2,516,139 | $51.0M | 0.00% | +305,816+13.8% | Added |
| RTW Investments, LP | 3,152,341 | $63.8M | 1.00% | +271,640+9.4% | Added |
| Deerfield Management Company, L.P. (Series C) | 0 | $0 | 0.00% | −754,042−100.0% | Sold out |
| Soleus Capital Management, L.P. | 0 | $0 | 0.00% | −250,000−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −106,900−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −55,262−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| CIBC World Markets Corp | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Ghisallo Capital Management LLC | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Endurant Capital Management LP | 0 | $0 | 0.00% | −47,649−100.0% | Sold out |
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −43,707−100.0% | Sold out |
| Channing Capital Management, LLC | 0 | $0 | 0.00% | −21,223−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −19,344−100.0% | Sold out |
| HSBC Holdings PLC | 0 | $0 | 0.00% | −12,903−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −10,600−100.0% | Sold out |
| Raymond James & Associates | 0 | $0 | 0.00% | −10,111−100.0% | Sold out |
| Quadrant Capital Group LLC | 0 | $0 | 0.00% | −130−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −43−100.0% | Sold out |
| Tucker Asset Management LLC | 0 | $0 | 0.00% | −4−100.0% | Sold out |